Patent application paves the way for a potential breakthrough in chronic pain treatment, offering renewed hope for millions BOSTON , Nov. 14, 2024 /PRNewswire/ -- CureLab Oncology , a clinical-stage biotech company dedicated to pioneering innovative therapies, announced a patent application for an innovative chronic pain treatment centered on its p62/SQSTM1 DNA plasmid. This development, which leverages CureLab's chronic inflammation therapeutic, Elenagen TM, signifies a potential paradigm shift in addressing chronic pain, a pervasive health challenge that affects millions globally.
With this patent, CureLab Oncology aims to address the limitations of existing chronic pain treatments, such as NSAIDs (nonsteroidal anti-inflammatory drugs), acetaminophen, COX-2 inhibitors, antidepressants, anti-seizure medications, and opioids. While these medications offer varying degrees of pain relief, they often come with a range of side effects, including gastrointestinal problems, kidney problems, stomach bleeding, ulcers, dizziness, drowsiness, nausea, and potential addiction. The patent emphasizes the urgent need for more effective chronic pain medications with fewer side effects.
The patent application encompasses the utilization of p62/SQSTM1 DNA to combat a wide spectrum of chronic pain conditions, including arthritis, back pain, headaches, cancer pain, neuropathic pain, and fibromyalgia. This therapeutic strategy operates by modulating the body's inflammatory response, a critical fa.
